BIVI (biovieinc.com) Net Profit

Official company branding of BioVie (BIVI)

BioVie Inc. is implementing IT modeling to combat dementia and cirrhosis, a move supported by the company's accumulated earnings. The value of -0.02 serves as the baseline for the current yield parameter. Business prospects rely on the launch of small molecules for liver therapy. The company is currently accumulating resources to complete the final stage of clinical trials for Parkinson's and Alzheimer's disease treatments.

BIVI (BioVie Inc) Company Net Income history from 07/04/2022 to 10/30/2026

Comprehensive metric breakdowns and analytics for biovieinc.com (BIVI)

- price and consensus price forecast:
Stock Quotes BioVie|BIVI - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization BIVI|BIVI - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share BioVie|BIVI - Company Book Value|Market Value to Book Value Ratio biovieinc.com|BIVI - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient BioVie Inc.|BIVI - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity BioVie|BIVI - Company Aggregate Debts|Debts to Book Value BIVI|BIVI - Company Long-Term Debt|Company Short-Term Loans and Borrowings BioVie|Quick Liquidity biovieinc.com
- net income and valuation multiples indicators:
BIVI - Net Profit
Fundamental valuation:BIVI BioVie Pharma
Mass-produced product of BioVie

Market expectations for BioVie Inc. (BIVI) depend on the company's ability to monetize its developments, where daily net income dynamics measure real operational resilience and the capital burn rate. Analyzing the company's financial profit, an investor sees how pipeline diversification between neuropathologies and liver diseases mitigates binary risks, transforming this high-risk asset into a more balanced biotechnological instrument.

Main competitors

Net Income Arrowhead Corp|MIRM (Mirum Pharmaceuticals) - Net Profit|Net Profit Dynavax Corp|Net Income ABUS (Arbutus Biopharma Corporation)|IVA (Inventiva SA) - Final Profit|Company Net Income Gyre Corp GYRE|Assembly Corp - Company Net Income|Galectin - Net Profit|Net Financial Result Genfit S.A. GNFT|DRRX (durect.com) - Net Income|ALGS (Aligos Therapeutics, Inc.) - Company Net Income|GLMD (Galmed Pharmaceuticals Ltd) - Net Profit|Company Net Income ENDRA Corp NDRA|Company Net Income Hepion Pharmaceuticals (HEPA)